Pharmaceutical compositions for the treatment of cancer

A chemotherapeutically active pharmaceutical composition comprising at least one pharmaceutically acceptable seleno amino acid derivative compound for use in the treatment of liver or pancreas cancer, the pharmaceutically acceptable seleno amino acid derivative compound including selenocysteine, selenocystine, selenium-methyl-L-selenocysteine or a pharmaceutically acceptable salt or ester thereof, wherein said chemotherapeutically active pharmaceutical composition is used in combination with an agent capable of increasing cytotoxicity of the pharmaceutically acceptable seleno amino acid derivative compound, the agent capable of increasing cytotoxicity of the pharmaceutically acceptable seleno amino acid derivative compound is selected from the group consisting of:

• α-keto-γ-methylthiobutyrate, dimethyl-2-oxoglutarate, pyridoxal 5′-phosphate hydrate, homoserine, DL-propargylglycine, 2-amino-2-methyl-1,3-propanediol, N-N-dimethyl formamide, 3-indoleacetic acid, a mutant kynurenine aminotransferase I protein having a Tyr to His substitution at position 101 or a His to Phe substitution at position 279, a nucleic acid sequence coding for the mutant kynurenine aminotransferase I protein and mixtures thereof.